Warning: The NCBI web site requires JavaScript to function. more...
Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
Schwartzman S, Fleischmann R, Morgan GJ Jr.
Arthritis Res Ther. 2004;6 Suppl 2:S3-S11. Epub 2004 Jun 21. Review.
Related citations
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.
Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.
Moreland LW.
Pharmacoeconomics. 2004;22(2 Suppl 1):39-53. Review. Erratum in: Pharmacoeconomics. 2004;22(8):547.
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.
[Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].
Pérez Pampín E, Gómez-Reino Carnota JJ.
Med Clin (Barc). 2008 Feb 16;130(5):179-87. Review. Spanish.
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.
Arthritis Rheum. 2004 May;50(5):1400-11.
Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A.
Drug Saf. 2002;25(3):173-97. Review.
[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S, Ferraccioli G, Ferri C, Galeazzi M, Lapadula G, Cerinic MM, Montecucco C, Triolo G, Trotta F, Valentini G.
Reumatismo. 2009 Apr-Jun;61 Suppl 1:1-23. Italian.
Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
Sizova L.
Br J Clin Pharmacol. 2008 Aug;66(2):173-8. Epub 2008 May 15. Review.
[New drugs and treatment strategies for rheumatoid arthritis].
Fantini F.
Recenti Prog Med. 2003 Sep;94(9):361-79. Review. Italian.
[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
Tijhuis GJ, van de Putte LB, Breedveld FC.
Ned Tijdschr Geneeskd. 2001 Sep 29;145(39):1880-5. Review. Dutch.
Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.
Hamilton K, Clair EW.
Expert Opin Pharmacother. 2000 Jul;1(5):1041-52. Review.
Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
[No authors listed]
Prescrire Int. 2010 Feb;19(105):30-4. Review.
Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B, Rahman M, Waters HC, Callegari P.
Clin Ther. 2008 Jul;30(7):1375-84.
Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
Doan QV, Chiou CF, Dubois RW.
J Manag Care Pharm. 2006 Sep;12(7):555-69. Review.
Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
Wisłowska M, Jakubicz D.
Rheumatol Int. 2007 May;27(7):641-7. Epub 2007 Jan 18.
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Clark W, Jobanputra P, Barton P, Burls A.
Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. Review.
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.
Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.
Biologics in rheumatoid arthritis.
Sharma PK, Hota D, Pandhi P.
J Assoc Physicians India. 2004 Mar;52:231-6. Review.
Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA, Klingman D, Hazard E, Ray S.
Clin Ther. 2009 Apr;31(4):825-35.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on